BioNTech Results Presentation Deck
Harnessing the Power of the Immune System to Address Serious Diseases
●
1 MARKETED
VACCINE
8
Infectious Disease
1 PHASE 1
PROGRAM
Validated mRNA technology
• Flexible & adaptable platform
• Speed in clinical development
●
Global manufacturing network
• Large safety database with proven path to regulatory approval
Focus on significant global health needs, including COVID-
19¹, malaria², HIV³, TB³, influenza¹
9 PRECLINICAL
PROGRAMS
Broaden Disease Horizon:
●
¹Collaboration with Pfizer; 2Collaboration with KENUP Foundation; ³Collaboration with Bill & Melinda Gates Foundation
●
●
15 PROGRAMS IN
19 CLINICAL TRIALS
Oncology
4 RANDOMIZED
PHASE 2 PROGRAMS
Sophisticated toolbox of technologies across 4 drug classes
Diverse and complementary modes of action
Novel therapeutic targets
Potential for synergistic combinations
Single agent objective responses in multiple Phase 1 trials.
Focus on broad range of solid tumors with the potential to
improve treatment paradigms
Autoimmune and inflammatory diseases, regenerative medicine
BIONTECHView entire presentation